25 -1 (21) 2018 — Khudayarova N.K., Kutlikova N.M., — MICROALBUMINURIUM AS A SPECIAL PROGNOSTIC MARKER FOR HEART FAILURE

MICROALBUMINURIUM AS A SPECIAL PROGNOSTIC MARKER FOR HEART FAILURE

Khudayarova N.K., Andijan State Medical Institute

Kutlikova N.M., Andijan State Medical Institute

Yuldasheva G.B., Andijan State Medical Institute

Sadikova D.T., Andijan State Medical Institute

Raubzhonov Kh. M. Andijan State Medical Institute

Resume,

Numerous works in recent decades have been devoted to the study of the clinical, including prognostic, importance of microalbuminuria (MAU), methods for its detection and quantification, as well as therapeutic measures aimed at combating this pathological condition.

Keywords: microalbuminuria, prognosticmarker, heartfailure, pathologicalcondition.

First page

88

Last page

90

For citation: Khudayarova N.K., Kutlikova N.M., Yuldasheva G.B., Sadikova D.T., Raubzhonov Kh. M. Microalbuminurium as a special prognostic marker for heart failure //New Day in Medicine 1(21)2018 88-90 https://cutt.ly/XneogCk

List of References

1. Diercks G.F., van Boven A.J., Hillege H.L., Janssen W.M., Kors J.A., de Jong P.E., Grobbee D.E., Crijns H.J., van Gilst W.H. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. // Eur Heart J. 2000 Dec;21(23):1922- 7.
2. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy //Lancet 2000 Sep 2:356(9232):860.
3. Gerstein H.C., Mann J.F., Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals// JAMA, 2001; 286: 421-6.
4. Karalliedde J., Viberti G. Microalbuminuria and cardiovascular risk//Am J Hypertens 2004; 17: 986-93.
5. Klausen K., Johnsen K.B., Rasmussen F. et al. Very low levels of microalbuminuria are associated with an increased risk of coronary heart disease and death independent of renal function, hypertension, and diabetes//Am Heart Association 2004; 110:32­35.
6. Klausen K., Scharling H., Jensen J. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases //Intern. Med. – 2006; 260 (3): 231-237.
7. Pedrinelli R., Dell’Omo G., Di Bello V. et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension//J Hum Hypertens, 2002; 16: 79-89.
8. Rein P., Boehnel C., Vonbank A. et al. Albuminuria is associated with angiographically determined coronary atherosclerosis both in patients with type 2 diabetes and in non-diabetic individuals/ /European Heart Journal, 2010; Vol. 31 (Abstract Supplement) :802.
9. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria//Lancet 1997; 349: 1787-92.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)//Lancet 1998;352:837-53.
11. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P; DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study//Diabetes Care. 2003 Mar;26(3):855-60.
12. Volpe M. Microalbuminuria screening in patients with hypertension: Recommendations for clinical practice//Int J ClinPract 2008, 62 (1): 97-108.
13. Wachtell K., Ibsen H., Olsen M.H. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study//Ann Intern Med, 2003; 139: 901-6.